Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

CVS Health Corp (CVSCL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
57,949.00 0.00    0.00%
10/10 - Closed. Currency in CLP ( Disclaimer )
Type:  Equity
Market:  Chile
ISIN:  US1266501006 
  • Volume: 30
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 62,795.00 - 62,795.00
CVS Health Corp 57,949.00 0.00 0.00%

NYSE:CVSCL Financials

 
A brief overview of the NYSE:CVS financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of CVS over time.

CVS Health Corporation reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 30,667 million compared to USD 25,108 million a year ago. Revenue was USD 91,234 million compared to USD 88,921 million a year ago. Net income was USD 1,770 million compared to USD 1,901 million a year ago. Basic earnings per share from continuing operations was USD 1.41 compared to USD 1.48 a year ago. Diluted earnings per share from continuing operations was USD 1.41 compared to USD 1.48 a year ago.For the six months, sales was USD 61,058 million compared to USD 49,460 million a year ago. Revenue was USD 179,671 million compared to USD 174,199 million a year ago. Net income was USD 2,883 million compared to USD 4,037 million a year ago. Basic earnings per share from continuing operations was USD 2.29 compared to USD 3.15 a year ago. Diluted earnings per share from continuing operations was USD 2.28 compared to USD 3.13 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CVSCL Income Statement

Gross margin TTM 14.37%
Operating margin TTM 3.19%
Net Profit margin TTM 1.99%
Return on Investment TTM 5.44%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 90840 87983 93545 89487
Gross Profit 12989 12107 13608 13300
Operating Income 2753 1877 3438 3518
Net Income 1770 1113 2046 2261

CVSCL Balance Sheet

Quick Ratio MRQ 0.37
Current Ratio MRQ 0.86
LT Debt to Equity MRQ 81.76%
Total Debt to Equity MRQ 111.87%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 252481 249743 249728 251306
Total Liabilities 177370 175593 173092 176796
Total Equity 75111 74150 76636 74510

CVSCL Cash Flow Statement

Cash Flow/Share TTM 6.43
Revenue/Share TTM 288.25
Operating Cash Flow  3.80%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3089 4903 -2636 2716
Cash From Investing Activities -1625 -2094 -1242 -771
Cash From Financing Activities 1249 -1227 -972 -2697
Net Change in Cash 2713 1582 -4850 -752
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CVS Comments

Write your thoughts about CVS Health Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
soyda yukno
soyda yukno Sep 11, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
absolute bargain now
Crim Jamer
Crim Jamer Sep 11, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Waiting for 49
Jim McDonald
Jim McDonald Aug 13, 2024 9:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's management imo. I believe Lynch's position is on the line and so, she'll get it on track or they will fire her like they should have already done, and her replacement will right the ship. It may take quite a while, but they won't let it fail.
Jordan Alvaredo
Jordan Alvaredo Aug 10, 2024 4:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bargain
Peter Sagan
Peter Sagan Aug 10, 2024 4:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I agree
Argenis Quintero
Argenis1979 Aug 07, 2024 6:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not bad results
Steven Bellenot
Steven Bellenot Jul 07, 2024 6:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Walgreens CEO: 'We don't need to own a health plan in order to create value' CVS has gone in a different direction and this direction is better so CVS is better. Just how much upside this creates not sure. But this seems oversold. WBA is hopeless. WBA will follow Rite Aid. CVS will follow CI and UNH.
Pato Stefak
Pato Stefak Jul 02, 2024 1:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
brutal catastrophy, management must go out
Pato Stefak
Pato Stefak Jul 02, 2024 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wba folower, 15$ value
Pato Stefak
Pato Stefak Jul 01, 2024 1:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
incredible trash
Pato Stefak
Pato Stefak Jul 01, 2024 1:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
extrem garbage, sell to 30.
Pato Stefak
Pato Stefak Jul 01, 2024 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
garbage from israel.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email